At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 49 enrolled
Drug / intervention
ABP 938 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Two-Arm Study in Subjects With Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe
In Brief
A Phase 3 clinical trial evaluating ABP 938 and Aflibercept for Chorioretinal Vascular Disease. Completed, enrolled 49 participants across 4 sites.
Detailed Summary
The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChorioretinal Vascular Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedJan 2023
Primary CompletionFeb 2023
Study CompletionMar 2023
TodayJul 2026
First PostedJan 30, 2023
Enrollment StartJan 23, 2023
Primary CompletionFeb 17, 2023
Study CompletionMar 24, 2023
TodayJul 2, 2026
Enrollment to primary: 24 daysPosted 3.4 years ago
Interventions
ABP 938drug
IVT injection
Afliberceptdrug
IVT injection